Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease.
Ruan
Cheng-Huai
CH
Department of Internal Medicine, New York Hospital Medical Center of Queens/Weil Cornell Medical College Affiliated Hospital, Flushing, NY 11355, United States. chr9062@nyp.org
So
Shui-Ping
SP
Ruan
Ke-He
KH
D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D015153:Blotting, Western; D019556:COS Cells; D002318:Cardiovascular Diseases / Q000378:metabolism / Q000503:physiopathology; D002522:Chlorocebus aethiops; D002851:Chromatography, High Pressure Liquid; D051545:Cyclooxygenase 1 / Q000378:metabolism* / Q000502:physiology; D051546:Cyclooxygenase 2 / Q000378:metabolism* / Q000502:physiology; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D004591:Electrophoresis, Polyacrylamide Gel; D011464:Epoprostenol / Q000096:biosynthesis*; D008856:Microscopy, Fluorescence
D052246:Cyclooxygenase 2 Inhibitors; D016718:Arachidonic Acid; D011464:Epoprostenol; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2